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Abstract 
The treatment goals for metastatic breast cancer (MBC) are prolonging survival and improving the quality of life. 
Eribulin, a non-taxane tubulin inhibitor, demonstrated improved survival in previous studies and also showed mild 
toxicity when used in late-line therapy for MBC. We conducted a phase II study to investigate the efficacy of eribulin 
mesylate as the first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative MBC. This was 
a phase II, open-label, single-arm, multicenter trial conducted in Japan. Patients with HER2-negative MBC received 
intravenous eribulin (1.4 mg/m2 on days 1 and 8 of each 21-day cycle). The primary efficacy outcome was overall 
response rate (ORR). Secondary outcomes included time to treatment failure, progression-free survival (PFS), overall 
survival (OS), and safety. A total of 35 patients were enrolled and received a median of 8 (range 1–21) cycles of eribulin 
therapy. ORR and clinical benefit rate were 54.3 and 62.9 %, respectively. Median PFS was 5.8 months and median 
OS was 35.9 months. Grade 3 or 4 neutropenia was observed in 63 % of patients. The majority of non-hematological 
adverse events were mild in severity. The present trial demonstrated that eribulin has antitumor activity comparable 
with other key established cytotoxic agents with acceptable safety and tolerability. Thus, eribulin as first-line chemo-
therapy might be beneficial for patients with HER2-negative MBC.
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Background
The prognosis for patients with human epidermal growth 
factor receptor 2 (HER2)-positive metastatic breast can-
cer (MBC) has improved significantly since anti-HER2 
therapies became commercially available. However, the 
long-term survival of patients with HER2-negative breast 
cancer remains poor, with a 5-year survival rate of only 
24.3  % for distant metastatic disease (Howlader et  al. 
2013). As MBC is currently incurable, the goals of therapy 
are to prolong survival, palliate symptoms, and optimize 
quality of life (QoL) (Partridge et  al. 2014). Anthracy-
cline- or taxane-based regimens have often been chosen 
as first-line therapy for HER2-negative MBC. The current 
guidelines suggest using a single agent to optimize both 
treatment length and QoL for first-line therapy, except 
in the case of immediately life-threatening disease (Par-
tridge et  al. 2014; Cardoso et  al. 2014). Based on these 
guidelines, agents with reduced toxicity but comparable 
efficacy to anthracyclines and taxanes could be therapeu-
tic options for first-line therapy in such patients. In fact, 
a recent clinical study conducted in Japan demonstrated 
non-inferiority of the oral 5-fluorouracil derivative S-1 in 
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overall survival (OS) and superiority in QoL against tax-
ane as first-line chemotherapy for MBC (Takashima et al. 
2016).
Recently, eribulin, a non-taxane microtubule dynam-
ics inhibitor belonging to the halichondrin class of anti-
neoplastic agents, which has a mechanism of action 
distinct from currently available taxanes (Jordan et  al. 
2005; Smith et al. 2010), has become available for treat-
ment of MBC. In a phase 3, open-label, randomized trial 
(EMBRACE study), eribulin showed a significant and 
clinically meaningful improvement in OS compared to 
treatment of the physician’s choice in patients with heav-
ily pretreated MBC (Cortes et  al. 2011). In a different 
trial, the survival benefit of eribulin was similar to that 
of capecitabine in patients with MBC who had previ-
ously been treated with anthracycline- and taxane-based 
regimens (Kaufman et  al. 2015). Moreover, the pooled 
analysis of those two trials demonstrated that eribulin 
significantly prolonged the OS compared with controls 
(Twelves et al. 2014). In addition to OS benefit, the non-
hematological toxicity reported with eribulin treatment 
is mostly mild. These two findings suggest that eribulin 
would be a suitable option for early-line treatment of 
MBC to minimize toxicity and maximize survival benefit.
Although eribulin has been approved in Japan for the 
treatment of patients with inoperable or recurrent breast 
cancer, and is not limited to those who have been previ-
ously treated with chemotherapy regimens, data on first-
line use of eribulin for treatment of Japanese patients 
with MBC are still limited. To date, only one phase II trial 
conducted outside Japan has included a small number of 
Asian patients with MBC (McIntyre et  al. 2014). More-
over, current guidelines do not specify a preferred regi-
men for HER2-negative MBC. Therefore, we conducted 
a phase II trial to investigate the efficacy and safety of 




Key inclusion criteria included: female patients with 
histologically confirmed HER2-negative MBC (includ-
ing patients with unresectable advanced disease); aged 
≥20 and <75 years; no history of chemotherapy for MBC 
other than peri-operative therapy (patients who received 
hormone therapy, immunotherapy, or local radiotherapy 
for MBC could be included in this trial); at least 6 months 
since the last administration of neoadjuvant or adjuvant 
chemotherapy; Eastern Cooperative Oncology Group 
performance status (ECOG PS) of 0 or 1; having meas-
urable lesion(s) based on the Response Evaluation Cri-
teria in Solid Tumors (RECIST) ver. 1.1 (New response 
evaluation criteria in solid tumours 2009); and adequate 
bone marrow, liver, renal, and lung functions. Key exclu-
sion criteria included: hypersensitivity to eribulin; sys-
temic infection; uncontrolled pleural effusion/ascites or 
pericardial effusion; symptomatic brain tumor; serious 
complications, active concomitant malignancy; preg-
nancy (including possible pregnancy) of premenopausal 
women. Patients who were considered ineligible by the 
investigator were also excluded.
Study design
This was a phase II, open-label, single-arm, multicenter 
trial conducted at eight sites in Japan. The study protocol 
and all amendments were approved by local ethics com-
mittees or the institutional review board at each study 
site. This trial was conducted in accordance with the 
Japanese Guidelines for Clinical Research of the Ministry 
of Health, Labor and Welfare and the Declaration of Hel-
sinki, as well as other applicable regulatory requirements. 
All participants provided written informed consent prior 
to study entry. The present trial has been registered 
with the University Hospital Medical Information Net-
work (UMIN) Center (ID: UMIN000006086). This was 
an investigator-initiated clinical trial that was not sup-
ported by any industry funding, nor requested by any 
organization.
Eribulin was administered intravenously, without any 
premedication, at a dose of 1.4 mg/m2 over 2–5 min on 
days 1 and 8 of a 21-day cycle (2-weeks-on, 1-week-off). 
For patients who were not eligible for administration of 
eribulin on day 8 (i.e., neutrophil count <1000/mm3, 
platelet count <75,000/mm3, ≤grade 2 non-hematologi-
cal adverse events), the next cycle started on day 22. The 
dose was reduced to 1.1  mg/m2 if one of the following 
had occurred during the previous cycle: neutrophil count 
<500/mm3 for more than 7 days; presence of febrile neu-
tropenia; grade 4 thrombocytopenia; and grade 3 or 
higher non-hematological toxicity. The dose was further 
reduced to 0.7 mg/m2 if there was a toxicity as described 
above despite dose reduction to 1.1  mg/m2. Patients 
who were refractory to eribulin were able to continue 
treatment based on the choice of the investigator. Con-
comitant use of other anticancer therapy (e.g., hormone 
therapy, targeted therapy, immune therapy, and chemo-
therapy other than eribulin) and any local therapy was 
prohibited. Concomitant use of bone modifying agents 
was permitted if the agents had been used since prior to 
the study entry. Use of granulocyte colony-stimulating 
factor was permitted, but not for prophylactic adminis-
tration, by decision of the investigator based on the clini-
cal practice guideline (Smith et al. 2006).
The primary efficacy outcome was overall response 
rate (ORR), defined as the proportion of patients who 
achieved a complete response (CR) plus those who 
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achieved a partial response (PR). The secondary end-
points included progression-free survival (PFS), OS, time 
to treatment failure (TTF), and safety. Time to response 
and duration of response were also assessed.
Assessment
The information on patients’ characteristics at baseline 
was collected within 28  days prior to the initiation of 
eribulin administration. Baseline tumor assessments by 
radiographic evaluation (e.g., computerized tomography 
or magnetic resonance imaging scans) were also per-
formed within 28  days prior to the initiation of eribulin 
administration, and tumor assessments were performed 
by the same methods every 2 cycles thereafter. Tumor 
assessments were analyzed based on the RECIST ver. 1.1 
and classified as CR, PR, stable disease (SD), progres-
sive disease, or not evaluable. Tumor response was con-
firmed at least 4  weeks after the criteria for response 
were met. PFS was defined as the time from initiation of 
eribulin to disease progression or death from any cause, 
OS was defined as the time from initiation of eribulin to 
death from any cause, and TTF was defined as the time 
from initiation of eribulin to treatment discontinuation 
for any reason (e.g., disease progression, treatment tox-
icity, patient preference, or death). Time to response was 
the time from initiation of eribulin to documentation of 
tumor response and duration of response was defined as 
the time from documentation of tumor response to dis-
ease progression, which was assessed among patients who 
reached ORR. For safety, adverse events, physical exami-
nation, vital signs, laboratory tests, and tumor markers 
(i.e., carcinoembryonic antigen and breast cancer antigen 
15-3) were assessed during the study. All adverse events 
were graded according to the Common Terminology Cri-
teria for Adverse Events ver. 4.0 (CTEP 2015).
Statistical analysis
The following assumptions were made to determine tar-
get enrollment. In the EMBRACE study (Cortes et  al. 
2011), ORR for patients who received eribulin after a 
median of four previously administered regimens was 
12  %. In addition, ORR of nanoparticle albumin-bound 
paclitaxel and paclitaxel for MBC was reported as 33 and 
19 %, respectively, in all patients and 42 and 27 %, respec-
tively, in the subgroup (40  % of the full cohort) who 
received those agents as first-line therapy in the phase III 
trial (Gradishar et  al. 2005). Based on those results, we 
set threshold and expected values of ORR as 20 and 40 %, 
respectively. To meet the threshold and expected values 
of ORR with 80  % power and one-sided alpha error of 
0.05, at least 32 patients were needed. Thus, we aimed to 
enroll 35 patients with the expectation of approximately 
10 % ineligible patients.
Primary efficacy outcome (proportion of patients who 
achieved CR or PR for at least 4 weeks) was assessed in 
the full analysis set, which included all patients who 
received at least one dose of eribulin. In addition, clini-
cal benefit rate (CBR) was defined as the proportion 
of patients who achieved CR, PR, or SD for at least 
24 weeks. The median values with 95 % confidence inter-
val (CI) for PFS, and OS curves were estimated with the 
Kaplan–Meier method. TTF, time to response, and dura-
tion of response were presented as median values with 
ranges. The safety analysis was also conducted in the full 
analysis set. All statistical analyses were one-sided, and 




A total of 35 patients with HER2-negative MBC were 
enrolled between September 2011 and May 2014; none 
were excluded from our primary analysis. The charac-
teristics of the patients at baseline are summarized in 
Table  1. The median age was 64  years (range 40–75), 
and the all patients had ECOG PS 0 or 1. Twenty-eight 
patients (80  %) were hormonal receptor-positive. Ten 
patients (29  %) received perioperative chemotherapy 
with anthracycline and/or taxane and five patients (14 %) 
received perioperative chemotherapy with other agents. 
The median number of cycles of eribulin administra-
tion was 8 (range 1–21), and the median relative dose 
intensity per week was 91.6 % (range 44.7–100 %). Dose 
modification was needed in four patients, and schedule 
modification in 19 patients. Patients were followed up for 
a median of 23.0 months (range 1.0–48.6) at data cut-off 
(October 15, 2015).
Efficacy analysis
The ORR was 54.3 % (95 % CI 37.8–70.8) and CBR was 
62.9 % (95 % CI 46.8–78.9) (Table 2; Fig. 1). Among eight 
patients with locally advanced disease, four discontin-
ued eribulin therapy and were able to undergo surgery as 
a result of down-staging. In the subgroups stratified by 
estrogen receptor status of the tumor, ORR for patients 
with luminal-like disease and those with triple-negative 
disease was somewhat similar; 53.6 % (95 % CI 35.1–72.0) 
and 57.1  % (95  % CI 20.5–93.8), respectively. ORR for 
patients with a disease-free interval of <2 or ≥2  years 
was similar. On the other hand, ORR for patients who 
did not receive any neoadjuvant/adjuvant chemother-
apy was higher at 70.0 % (95 % CI 49.9–90.1) compared 
to 33.3 % (95 % CI 9.5–57.2) in those who received neo/
adjuvant chemotherapy. In addition, ORR for patients 
who received neo/adjuvant chemotherapy without 
anthracycline- or taxane-based regimens was higher at 
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64.0 % (95 % CI 45.2–82.8) compared to 30.0 % (95 % CI 
1.6–58.4) in those who received anthracycline- or taxane-
based neo/adjuvant chemotherapy. Moreover, patients 
without visceral metastasis had higher ORR at 66.7  % 
(95 % CI 40.0–93.3) compared to 47.8 % (95 % CI 27.4–
68.2) in those with visceral metastasis.
The median PFS was 5.8 months (95 % CI 4.8–8.1) and 
median OS was 35.9  months. (Figs.  2, 3). The median 
TTF was 5.3 months (range 4.1–6.8), the median time to 
response was 1.4 months (range 1.2–3.7), and the median 
duration of response among patients who reached ORR 
was 4.6 months (range 0.6–22.1).
Safety analysis
Observed adverse events are shown in Table 3. Hemato-
logical adverse events of any grade were reported in all of 
the patients. The most commonly reported grade 3 or 4 
hematologic adverse event was neutropenia (22 patients; 
62.9  %), followed by leucopenia (9 patients; 25.7  %). 
Febrile neutropenia was reported in two patients (5.7 %). 
The most commonly reported any grade non-hemato-
logical adverse event was alopecia (26 patients; 74.3 %), 
followed by fatigue (22 patients; 62.9 %), sensory neurop-
athy (21 patients; 60.0 %), and fever (17 patients; 48.6 %). 
Grade 3 or higher non-hematologic adverse events were 
reported in three patients (8.6  %); sensory neuropathy, 
mucositis, and skin rash in one patient (2.8 %) each. Five 
patients (14.3  %) discontinued eribulin therapy due to 
adverse events.
Increases in laboratory values were reported as follows: 
aspartate aminotransferase (29 patients; 82.9 %), alanine 
aminotransferase (29 patients; 82.9 %), gamma-glutamyl 
transpeptidase (13 patients; 37.1 %), alkaline phosphatase 
(9 patients; 25.7  %), bilirubin (9 patients; 25.7  %), and 
albumin (9 patients; 25.7 %). Grade 3 events of increased 
aspartate aminotransferase, alkaline phosphatase, and 
albumin were reported in one patient each (2.9  %), and 
Grade 3 increase of gamma-glutamyl transpeptidase was 
reported in two patients (5.7 %). No Grade 3 increase of 
alanine aminotransferase or Grade 4 non-hematologic 
toxicity was reported. The majority of changes in labora-
tory values and vital signs were not clinically significant. 
There were no serious adverse events reported.
Discussion
The current phase II study was to the first to investigate 
the efficacy and safety of eribulin as first-line chemother-
apy for HER2-negative MBC in Japanese patients. The 
ORR and CBR were high, at 54.3 and 62.9 %, respectively. 
Interestingly, the ORR was higher in patients who had 
not received any neo/adjuvant chemotherapy, whose dis-
ease had luminal-like or triple negative features, or who 
had distant metastasis, than in those who had received 
neo/adjuvant chemotherapy. Hematological and non-
hematological toxicities of any grade were reported in all 
of the patients; however, the majority of non-hematolog-
ical adverse events were mild and tolerable. All reported 
adverse events were expected and no unexpected adverse 
events were reported.
The ORR and CBR (54.3 and 62.9  %, respectively) in 
this phase II trial were higher than those in a global 
Table 1 Patient characteristics at baseline
ECOG PS, Eastern Cooperative Oncology Group performance status
Variable n
Patients 35
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phase II trial conducted by McIntyre et  al. (28.6 and 
51.8 %, respectively) (McIntyre et al. 2014), which might 
be due to differences in the proportion of patients who 
had received neo/adjuvant chemotherapy. In our trial, 
the ORR was higher in patients who had not received 
any neo/adjuvant chemotherapy than in those who had 
(70.0 vs. 33.3 %). Among patients who had received neo/
adjuvant chemotherapy, patients who had not received 
anthracycline- or taxane-based regimens had higher 
ORR than those who had received anthracycline- or tax-
ane-based neo/adjuvant chemotherapy (64.0 vs. 30.0 %). 
Our trial included a smaller proportion of patients 
who had received neo/adjuvant chemotherapy (43  %) 
than McIntyre’s trial (68  %). In addition, only 29  % of 
the patients included in our trial had received anthra-
cycline- or taxane-based neo/adjuvant chemotherapy, 
Table 2 Overall response rate
CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, CBR clinical benefit rate, A/T 
anthracycline- or taxane-based regimens, W/O without, TN triple negative, yr years, Op operation
n (%) Overall Neoadjuvant/adjuvant chemotherapy Subtype Visceral metastasis Disease free interval
Yes No With A/T W/O A/T Luminal TN Yes No <2 yr ≥2 yr W/O Op.
Patients 35 (100) 15 (42.9) 20 (57.1) 10 (28.6) 25 (71.4) 28 (80.0) 7 (20.0) 23 (65.7) 12 (34.3) 7 (20.0) 14 (40.0) 14 (40.0)
CR 2 (5.7) 1 (6.7) 1 (5.0) 0 (0.0) 2 (8.0) 2 (7.1) 0 (0.0) 1 (4.3) 1 (8.3) 0 (0.0) 1 (7.1) 1 (7.1)
PR 17 (48.6) 4 (26.7) 13 (65.0) 3 (30.0) 14 (56.0) 13 (46.4) 4 (57.1) 10 (43.5) 7 (58.3) 3 (42.9) 5 (35.7) 9 (64.3)
SD ≥ 24 w 3 (8.6) 2 (13.3) 2 (10.0) 1 (10.0) 3 (12.0) 3 (10.7) 1 (14.3) 3 (13.0) 1 (8.3) 2 (28.6) 1 (7.1) 1 (7.1)
SD < 24 w 8 (22.9) 5 (33.3) 2 (10.0) 4 (40.0) 3 (12.0) 5 (17.9) 2 (28.6) 4 (17.4) 3 (25.0) 1 (14.3) 5 (35.7) 1 (7.1)
PD 2 (5.7) 1 (6.7) 1 (5.0) 0 (0.0) 2 (8.0) 2 (7.1) 0 (0.0) 2 (8.7) 0 (0.0) 0 (0.0) 1 (7.1) 1 (7.1)
NE 3 (8.6) 2 (13.3) 1 (5.0) 2 (20.0) 1 (4.0) 3 (10.7) 0 (0.0) 3 (13.0) 0 (0.0) 1 (14.3) 1 (7.1) 1 (7.1)
ORR 19 (54.3) 5 (33.3) 14 (70.0) 3 (30.0) 16 (64.0) 15 (53.6) 4 (57.1) 11 (47.8) 8 (66.7) 3 (42.9) 6 (42.9) 10 (71.4)
CBR 22 (62.9) 7 (46.7) 16 (80.0) 4 (40.0) 19 (76.0) 18 (64.3) 5 (71.4) 14 (60.9) 9 (75.0) 5 (71.4) 7 (50.0) 11 (78.6)
Fig. 1 Percentage change in total sum of target lesion diameters 
from baseline to postbaseline nadir
Fig. 2 Kaplan–Meier plot of progression-free survival
Fig. 3 Kaplan–Meier plot of overall survival
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while in McIntyre’s trial, 48 and 46  % of patients had 
received anthracycline- or taxane-based neo/adjuvant 
chemotherapy, respectively. Consequently, the lower 
proportion of patients in our trial who had received neo/
adjuvant chemotherapy, especially anthracycline- or 
taxane-based neo/adjuvant chemotherapy, might have 
led to the higher ORR. Moreover, the ORRs were com-
parable to those with nanoparticle albumin-bound pacli-
taxel (42 %) and higher than those with paclitaxel (27 %) 
as first-line chemotherapy for MBC as shown in a phase 
III trial conducted outside Japan (Gradishar et al. 2005). 
The median time to response and duration of response 
(1.4 and 4.6  months, respectively) among patients who 
reached ORR in our trial were similar to those in McIn-
tyre’s trial (1.4 and 5.8  months, respectively) (McIntyre 
et al. 2014).
The median PFS in this trial (5.8 months) was compa-
rable to that reported in earlier clinical trials, including a 
study of first-line use of taxane (5.1 months) and anthra-
cycline (7.2  months) for MBC (Piccart-Gebhart et  al. 
2008) and the phase II trial of eribulin conducted out-
side Japan (6.8 months) (McIntyre et al. 2014). Addition-
ally, the median OS was 35.9 months in our trial, which 
seems to be comparable to taxane (37.2  months) and 
S-1 (35.0  months) for MBC in the Japanese population 
(Takashima et  al. 2016). The survival benefit of eribu-
lin has also been demonstrated in late-line therapy for 
MBC (Cortes et  al. 2011; Kaufman et  al. 2015; Twelves 
et al. 2014). One of the characteristics of eribulin is that 
it is associated with improvements in OS, but not PFS. 
This finding has also been noted with tumors other than 
breast cancer. A recent phase III trial of eribulin versus 
dacarbazine in patients with leiomyosarcoma and adi-
pocytic sarcoma demonstrated that the median OS was 
significantly improved in patients treated with eribulin 
compared with those treated with dacarbazine, although 
median PFS was comparable between the patient groups 
(Schöffski et  al. 2015). The survival benefit of eribulin 
might be due to improvement of the microenvironment 
of tumor cells, which was demonstrated by in vitro and 
in vivo preclinical studies (Funahashi et al. 2014; Yoshida 
et al. 2014; Terashima et al. 2014). Since one of the major 
goals of the therapy for MBC is to prolong survival, 
eribulin might be a suitable option to achieve this goal.
Overall, the safety of eribulin was acceptable, although 
five patients (14.3 %) discontinued therapy due to adverse 
events. The majority of non-hematological adverse events 
were mild in severity. Grade 3 or 4 sensory neuropathy, 
which might lead to discontinuation of eribulin therapy, 
was reported in only one patient. Among hematological 
adverse events, grade 3 or 4 neutropenia was reported in 
62.9  % of patients; thus eribulin should be administered 
with caution and patients should be monitored closely for 
severe neutropenia. However, since febrile neutropenia 
was reported in only two patients, the tolerability of eribu-
lin was considered to be acceptable. Notably, all reported 
adverse events were those that might be anticipated with 
this treatment and no new adverse events were reported 
in the first-line use of eribulin in this Japanese population. 
The proportion of patients who experience severe adverse 
events after initiation of eribulin is relatively low com-
pared to that after initiation of other key drugs for MBC 
(Cortes et  al. 2011; Kaufman et  al. 2015; McIntyre et  al. 
2014). Thus, many patients treated with eribulin might 
not experience deterioration of their QoL. The current 
guidelines suggest using a single agent to optimize both 
treatment length and QoL for first-line therapy, except in 
Table 3 Adverse events
NA not available, AST aspartate aminotransferase, ALT alanine aminotransferase, 
GTP gamma-glutamyl transpeptidase, ALP gamma-glutamyl transpeptidase
Adverse events N = 35
Any grade [n (%)] Grade 3/4 [n (%)]
Hematological
 Neutropenia 34 (97.1) 22 (62.9)
 Leucopenia 31 (88.6) 9 (25.7)
 Anemia 18 (51.4) 0 (0)
 Thrombocytopenia 18 (51.4) 0 (0)
 Febrile neutropenia 2 (5.7) 2 (5.7)
Non-hematological
 AST 29 (82.9) 1 (2.9)
 ALT 29 (82.9) 0 (0)
 Alopecia 26 (74.3) NA
 Fatigue 22 (62.9) 0 (0)
 Sensory neuropathy 21 (60.0) 1 (2.9)
 Fever 17 (48.6) 0 (0)
 Mucositis 13 (37.1) 1 (2.9)
 Γ-GTP 13 (37.1) 2 (5.7)
 Nausea 11 (31.4) 0 (0)
 Taste disturbance 11 (31.4) 0 (0)
 Anorexia 10 (28.6) 0 (0)
 ALP 9 (25.7) 1 (2.9)
 Skin rash 6 (17.1) 1 (2.9)
 Vomiting 4 (11.4) 0 (0)
 Constipation 4 (11.4) 0 (0)
 Diarrhea 4 (11.4) 0 (0)
 Arthralgia 4 (11.4) 0 (0)
 Edema 4 (11.4) 0 (0)
 Myalgia 3 (6.6) 0 (0)
 Motor neuropathy 2 (5.7) 0 (0)
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the case of immediately life-threatening disease (Partridge 
et al. 2014; Cardoso et al. 2014). Japanese guidelines (The 
Japanese Breast Cancer Society 2015) also support this 
statement and the oral 5-fluorouracil derivative S-1 has 
become a recommended first-line treatment for MBC, 
along with anthracycline and taxane based on a recent 
clinical trial conducted in Japan—this trial demonstrated 
non-inferiority of S-1 in OS and TTF over taxane; S-1 also 
demonstrated less toxicity and better QoL profile com-
pared to taxane (Takashima et  al. 2016). In this context, 
eribulin might also be a recommended first-line treat-
ment for MBC in the Japanese population, though further 
investigation is warranted.
Although the present trial offers meaningful data to 
evaluate efficacy and safety of first-line eribulin for treat-
ment of HER2-negative MBC in Japanese patients, some 
caution is needed in the interpretation of the results. 
The present phase II trial was an exploratory study and 
conducted without any comparator. In addition, since 
the number of patients included in this trial was small 
(N  =  35), caution is required for interpretation of OS 
data, due to lack of statistical power.
Conclusion
In conclusion, the present phase II trial investigated the 
efficacy and safety of eribulin as first-line chemotherapy 
in Japanese women with HER2-negative MBC, and dem-
onstrated that eribulin has antitumor activity comparable 
to that demonstrated by other key established cytotoxic 
agents. As eribulin has the potential to prolong survival 
in HER2-negative MBC patients, and has demonstrated 
acceptable safety and tolerability, it could be beneficial 
for such patients when used as a first-line therapy. Fur-
ther research is necessary to confirm the results of the 
present phase II trial.
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